Literature DB >> 25992458

Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review.

Liliana Aranha Caetano, António José Almeida, Lídia Maria Diogo Gonćalves.   

Abstract

Next-generation vaccines for tuberculosis should be designed to prevent the infection and to achieve sterile eradication of Mycobacterium tuberculosis. Mucosal vaccination is a needle-free vaccine strategy that provides protective immunity against pathogenic bacteria and viruses in both mucosal and systemic compartments, being a promising alternative to current tuberculosis vaccines. Micro and nanoparticles have shown great potential as delivery systems for mucosal vaccines. In this review, the immunological principles underlying mucosal vaccine development will be discussed, and the application of mucosal adjuvants and delivery systems to the enhancement of protective immune responses at mucosal surfaces will be reviewed, in particular those envisioned for oral and nasal routes of administration. An overview of the essential vaccine candidates for tuberculosis in clinical trials will be provided, with special emphasis on the potential different antigens and immunization regimens.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25992458

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  4 in total

Review 1.  Lipoarabinomannan in Active and Passive Protection Against Tuberculosis.

Authors:  Margarida Correia-Neves; Christopher Sundling; Andrea Cooper; Gunilla Källenius
Journal:  Front Immunol       Date:  2019-09-11       Impact factor: 7.561

2.  Detection of live M. bovis BCG in tissues and IFN-γ responses in European badgers (Meles meles) vaccinated by oropharyngeal instillation or directly in the ileum.

Authors:  Sandrine Lesellier; Maria-Laura Boschiroli; Jacques Barrat; Christoph Wanke; Francisco J Salguero; Waldo L Garcia-Jimenez; Alex Nunez; Ana Godinho; John Spiropoulos; Simonette Palmer; Dipesh Dave; Paul Anderson; Jean-Marc Boucher; Krystel de Cruz; Sylvie Henault; Lorraine Michelet; Sonya Gowtage; Gareth A Williams; Allan K Nadian; Elodie Monchâtre-Leroy; Frank Boué; Mark A Chambers; Céline Richomme
Journal:  BMC Vet Res       Date:  2019-12-06       Impact factor: 2.741

3.  Nanocarrier vaccines for SARS-CoV-2.

Authors:  Jatin Machhi; Farah Shahjin; Srijanee Das; Milankumar Patel; Mai Mohamed Abdelmoaty; Jacob D Cohen; Preet Amol Singh; Ashish Baldi; Neha Bajwa; Raj Kumar; Lalit K Vora; Tapan A Patel; Maxim D Oleynikov; Dhruvkumar Soni; Pravin Yeapuri; Insiya Mukadam; Rajashree Chakraborty; Caroline G Saksena; Jonathan Herskovitz; Mahmudul Hasan; David Oupicky; Suvarthi Das; Ryan F Donnelly; Kenneth S Hettie; Linda Chang; Howard E Gendelman; Bhavesh D Kevadiya
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 17.873

4.  Effect of Experimental Parameters on Alginate/Chitosan Microparticles for BCG Encapsulation.

Authors:  Liliana A Caetano; António J Almeida; Lídia M D Gonçalves
Journal:  Mar Drugs       Date:  2016-05-11       Impact factor: 5.118

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.